Open Access Highly Accessed Research article

A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis

Mario H Cardiel1*, Paul P Tak2, William Bensen3, Francis X Burch4, Sarka Forejtova5, Janusz E Badurski6, Tarundeep Kakkar7, Terry Bevirt8, Liyun Ni9, Ellen McCroskery10, Angelika Jahreis10 and Debra J Zack10

Author Affiliations

1 Centro de Investigacion Clinica de Morelia, Morelia, Virrey de Mendoza 1998-Int. 522 Col Félix Ireta, Mich 58070, Mexico

2 Department of Clinical Immunology/Rheumatology, Academic Medical Center/University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands

3 St Joseph's Hospital, McMaster University, 25 Charlton Avenue East, Hamilton, ON, L8N 1Y2, Canada

4 San Antonio Center for Clinical Research, 8527 Village Drive, San Antonio, TX 78217, USA

5 Revmatologicky ustav, Na Slupi 4, Praha 128 50, Czech Republic

6 Centrum Osteoporozy i Chorób Kostno-Stawowych, Waryńskiego 6/2, 15-461 Białystok, Poland

7 Pharmacokinetics and Drug Metabolism, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA

8 Global Development Operations, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA

9 Global Biostats and Epidemiology, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA

10 Global Development, General Medicine and Inflammation Therapeutic Area, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA

For all author emails, please log on.

Arthritis Research & Therapy 2010, 12:R192  doi:10.1186/ar3163

Published: 15 October 2010

Additional files

Additional file 1:

Investigator site list. Table listing the principal investigators and full study center details.

Format: DOC Size: 296KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data